|
Jul 19
|
Why Eli Lilly (LLY) is Emerging as a Dividend Growth Leader in Pharma for 2025
|
|
Jul 18
|
J.P. Morgan Sees Strong Q2 for Eli Lilly, Maintains Overweight Rating
|
|
Jul 18
|
Can Wegovy & Ozempic Drive Another Strong Quarter for Novo Nordisk?
|
|
Jul 18
|
Brokers Suggest Investing in Lilly (LLY): Read This Before Placing a Bet
|
|
Jul 18
|
Can Eli Lilly Stock Withstand the Threat of President Trump's New Sweeping Tariffs?
|
|
Jul 17
|
Eli Lilly vs. Merck: Which Drug Giant Appears Better Poised Today?
|
|
Jul 17
|
3 Stocks Including Grab Holdings That May Be Undervalued For Your Portfolio
|
|
Jul 17
|
This Pick Withstood the GLP-1 Challenge. Stick With the Stock.
|
|
Jul 16
|
Johnson & Johnson (JNJ) Q2 Earnings and Revenues Top Estimates
|
|
Jul 16
|
Johnson & Johnson (JNJ) Surpasses Q2 Earnings and Revenue Estimates
|
|
Jul 16
|
Trump Threatens Pharma Tariffs Soon. Why the Stocks Are Looking Healthy.
|
|
Jul 16
|
Johnson & Johnson shares jump after forecasting sales boost and milder tariff impact
|
|
Jul 16
|
Leading Drug Delivery Conference PODD Announces its 15th Annual Agenda
|
|
Jul 16
|
Tariffs Are Showing Up in Inflation. Why Trump Can’t Afford to Ditch Powell.
|
|
Jul 16
|
FDA invites more data from abroad — with a wary eye on China
|
|
Jul 16
|
Jim Cramer on Eli Lilly: “How Can You Leave This One Right Here?”
|
|
Jul 15
|
Trump Says Drug Tariffs Probable by Aug. 1, Downplays More Deals
|
|
Jul 15
|
Eli Lilly (LLY) Dips More Than Broader Market: What You Should Know
|
|
Jul 15
|
Health Care Roundup: Market Talk
|
|
Jul 15
|
Lilly’s Zepbound Faces a Potential Weight-Loss Rival. It’s Made by a Chinese Biotech.
|